These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31711789)

  • 1. Lipid update 2020 - Introduction and foreword.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):373-374. PubMed ID: 31711789
    [No Abstract]   [Full Text] [Related]  

  • 2. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.
    Virani SS
    Tex Heart Inst J; 2016 Aug; 43(4):313-4. PubMed ID: 27547139
    [No Abstract]   [Full Text] [Related]  

  • 3. AHA/ACC/Multisociety Cholesterol Guidelines: highlights.
    Jialal I; Devaraj S
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719881579. PubMed ID: 31590600
    [No Abstract]   [Full Text] [Related]  

  • 4. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
    Banach M; Penson PE
    Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid management beyond the guidelines.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):384-389. PubMed ID: 31669499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 7. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future.
    Stone NJ; Grundy SM
    Prog Cardiovasc Dis; 2019; 62(5):375-383. PubMed ID: 31733217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
    Handelsman Y; Lepor NE
    J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
    [No Abstract]   [Full Text] [Related]  

  • 9. Do Risk-Enhancing Factors Enhance Risk Estimation?
    Stern RH; Brook RD
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006078. PubMed ID: 31718296
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonstatin Therapy for Dyslipidemia.
    Ahmed HM; Nissen SE
    Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
    [No Abstract]   [Full Text] [Related]  

  • 11. HDL and Reverse Cholesterol Transport Biomarkers.
    Riggs KA; Rohatgi A
    Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.
    Navarese EP; Andreotti F; Raggi P; Kolodziejczak M; Buffon A; Bliden K; Tantry U; Kubica J; Sardella G; Lauten A; Agewall S; Gurbel PA; Brouwer MA
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):47-54. PubMed ID: 30247574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latest Updates on Lipid Management.
    Egom EE; Pharithi RB; Hesse S; Starr N; Armstrong R; Sulaiman HM; Gazdikova K; Mozos I; Caprnda M; Kubatka P; Kruzliak P; Khan B; Gaspar L; Maher VMG
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):85-100. PubMed ID: 30877603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
    Navar AM; Mulder HM; Wojdyla DM; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006019. PubMed ID: 31918581
    [No Abstract]   [Full Text] [Related]  

  • 16. It's never too early to beat your low-density lipoprotein cholesterol.
    Bergerot C; Angoulvant D; Lemesle G; Barone-Rochette G; Mewton N; Mach F
    Arch Cardiovasc Dis; 2021 Jan; 114(1):1-3. PubMed ID: 33509745
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: collecting new external evidence for cholesterol management.
    Streja D
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):121-3. PubMed ID: 26863279
    [No Abstract]   [Full Text] [Related]  

  • 18. LDL cholesterol: How low to go?
    Packard CJ
    Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The New 2018 Cholesterol Guidelines.
    Khera A
    Circulation; 2019 Jun; 139(25):2805-2808. PubMed ID: 30586686
    [No Abstract]   [Full Text] [Related]  

  • 20. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
    Robinson JG; Ray K
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.